Asthma and COPD Drugs Market Size, Share, and Trends

Asthma and COPD Drugs Market (By Diseases: Asthma, COPD; By Medication Class: Combination Drugs, Bronchodilators, Inhaled Corticosteroids (ICS), Short Acting Beta Agonists (SABA), Long Acting Beta Agonists (LABA), Leukotriene Antagonists (LTA), Anticholinergics, Anti-Inflammatories, Others; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032

  • Last Updated : October 2023
  • Report Code : 1711
  • Category : Healthcare

Asthma and COPD Drugs Market Size and Companies

The global asthma and COPD drugs market size was estimated at US$ 36 billion in 2022 and is expected to hit US$ 58.92 billion by 2032 with a registered CAGR of 5.10% from 2023 to 2032.

Asthma and COPD Drugs Market Size, Statistics 2023 to 2032

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare

Asthma and COPD Drugs Market in the U.S. 2023-2032

The U.S. asthma and COPD drugs market size was valued at US$ 1.61 billion in 2022 and is predicted to reach US$ 2.69 billion by 2032 with a growing CAGR of 7.40% from 2023 to 2032.

U.S. Asthma and COPD Drugs Market 2023 to 2032

North America dominated the asthma and COPD drugs market in 2022. The main factor for the growth of asthma and COPD drugs market in North America region is rising prevalence of asthma and COPD. Adult women are more likely than adult men to have asthma in the U.S. As per the Centers for Disease Control’s 2020 estimates, asthma affects about 25 million people in the U.S. This equates to roughly one in every thirteen Americans with 7% of children and 8% of adults falling in this category. Asthma affects around 20 million persons in the U.S. Thus, the surge in number of asthma patients is boosting the growth of asthma and COPD drugs market in the region.

Europe, on the other hand, is expected to develop at the fastest rate during the forecast period. The UK dominates the asthma and COPD drugs market in Europe region. The growth of the asthma and COPD drugs market in Europe region is attributed to the growing awareness of asthma and COPD among people. For example, the United Action for Allergy and Asthma was started in Europe in April 2017 to promote asthma knowledge across the globe. Thus, the asthma and COPD drugs market in this region is expected to grow at rapid pace in the near future.

Growth Factors

The factors such as growing geriatric population, technological developments, and rising prevalence of asthma and COPD are contributing towards the growth of global asthma and COPD drugs market. The COPD is growing at a faster rate globally. COPD is the third leading risk factor of death globally, as per the World Health Organization (WHO)’s 2021 datasheet, with 3.23 million fatalities in 2019. Over 80% of the deaths took place in low- and medium-income nations.

Moreover, the growing rate of asthma is also paving way for the growth of global asthma and COPD drugs market. As per the survey released in June 2019 by the Asthma and Allergy Foundation of America, asthma affects one out of every thirteen Americans. Furthermore, more than 11.4 million people with asthma had at least one asthma attack in 2017, according to the report.

In addition, the growing population of geriatrics is driving the growth of global asthma and COPD drugs market. As per the World Ageing 2020 estimate, the global population will be roughly 727 million people aged 65 and up in 2020. In 2050, the number of elderly people is expected to increase to 1.5 billion. Globally, the proportion of people aged 65 and more surged from 9.3% in 2020 to 16% in 2050. Thus, this factor is boosting the expansion of global asthma and COPD drugs market.

Another factor propelling the growth of global asthma and COPD drugs market is rising advancements in technologies and therapies as well as growing product launches by market players. For example, AstraZenca, a renowned pharmaceutical company, gained European Union (EU) approval for Trixeo Aerosphere for COPD supportive therapy in December 2020. The government of emerging and established regions is also heavily investing in the development of new drugs and medications. Some of the government bodies are collaborating with market players for the launch of new products. As a result, all of these aforementioned factors are boosting the expansion of global asthma and COPD drugs market.

Report Scope of the Asthma and COPD Drugs Market

Report Coverage Details
Market Size by 2032 USD 58.92 Billion
Growth Rate from 2023 to 2032

CAGR of 5.10%

Largest Market North America
Fastest Growing Market Europe
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered Diseases, Medication Class, Distribution Channel, Geography
Companies Mentioned Pfizer Inc., Teva Pharmaceutical Industries Ltd, Merck & Co. Inc, Grifols S.A., Novartis AG, Cipla Inc., Abbott, Astellas Pharma, Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals

 

Disease Insights

The asthma segment dominated the asthma and COPD drugs market in 2022. The asthma is considered as one of the life-threatening diseases around the world. According to World Health Organization (WHO), in 2019, asthma afflicted an estimated 262 million individuals, resulting 46,1000 mortalities. The most frequent chronic disorder among children is asthma. Inhaled medicine and drugs can help patients with asthma manage their symptoms and live a healthy life. Thus, the market for asthma and COPD drugs is expected to expand due to this factor.

Asthma and COPD Drugs Market Share, By Diseases, 2022 (%)

The CPOD segment is fastest growing segment of the asthma and COPD drugs market in 2022. According to the Institute of Health Metrics and Evaluation’s Global Burden of Disease Study (2016), there are 215 million cases with COPD worldwide. As per the World Health Organization (WHO), around 200 million people worldwide were diagnosed with COPD in 2016. The factors such as growing air pollution and toxic gases emissions are boosting the growth of asthma and COPD drugs market.

Medication Class Insights

The combination drugs segment dominated the asthma and COPD drugs market in 2022. The usage of combination of medications and drugs for the treatment of a variety of disorders has steadily increased during the past decade. The patients with COPD and asthma can now gain benefit from combination drugs according to several research studies.

The inhaled corticosteroids (ICS) segment is fastest growing segment of the asthma and COPD drugs market in 2022. The inhaled corticosteroids (ICS) aid in the prevention of asthma attacks as well as the improvement of lung function. They may also be utilized for the treatment of other lung disorders such as COPD. The inhaled corticosteroids (ICS) are quite effective for the treatment of asthma as compared to other types of drugs.

Key Developments

  • Nucala was authorized by the European Commission in August 2018 for the diagnosis of young patients with severe eosinophilic asthma in Europe. Due to the burden of the disorder is higher among children and adults, its approval will assist to satisfy a significant unsatisfied demand among the European people. Furthermore, the region’s options for treating severe asthma in children are limited.
  • The European Medicines Agency authorized GlaxoSmithKline PLC’s regulatory submission in February 2020, requesting a new indication for Trelegy Ellipta, a once daily, single inhaler triple therapy for the diagnosis of asthma in adults.
  • The U.S. Food and Drug Administration approved Cipla’s generic asthma inhaler, the generic counterpart of albuterol inhaler in April 2020, in response to asthma drug shortages caused by the COVID-19 issue. For asthmatics, this medicine is frequently used as a rescue medication.
  • Glenmark Pharmaceuticals introduced the Tiotropium Bromide dry powder inhaler under the trade name Tavulus in Spain in October 2021 for the diagnosis of COPD.
  • The favorable phase III ETHOS study results from AstraZeneca were released in the New England Journal of Medicine in July 2020. In patients with mild to high COPD, the triple combination medication PT010 was found to minimize the rate of mild to high symptoms when compared to dual combination treatments.

Some of the prominent players in the global asthma and COPD drugs market include:

  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd
  • Merck & Co. Inc
  • Grifols S.A.
  • Novartis AG
  • Cipla Inc.
  • Abbott
  • Astellas Pharma
  • Hoffmann-La Roche Ltd
  • Glenmark Pharmaceuticals

Segments Covered in the Report

(Note*: We offer report based on sub segments as well. Kindly, let us know if you are interested)

By Diseases

  • Asthma
  • COPD

By Medication Class

  • Combination Drugs
  • Bronchodilators
  • Inhaled Corticosteroids (ICS)
  • Short Acting Beta Agonists (SABA)
  • Long Acting Beta Agonists (LABA)
  • Leukotriene Antagonists (LTA)
  • Anticholinergics
  • Anti-Inflammatories
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Frequently Asked Questions

The global asthma and COPD drugs market size was reached at US$ 36 billion in 2022 and it is anticipated to worth around US$ 58.92 billion by 2032.

The global asthma and COPD drugs market is expected to drive growth at a CAGR of 5.10% from 2023 to 2032.

The major players operating in the asthma and COPD drugs market are Pfizer Inc., Teva Pharmaceutical Industries Ltd, Merck & Co. Inc, Grifols S.A., Novartis AG, Cipla Inc., Abbott, Astellas Pharma, Hoffmann-La Roche Ltd, and Glenmark Pharmaceuticals.

The global asthma and COPD drugs market is expected to rise due to reasons such as the ageing population, technological advancements, and the rising prevalence of asthma and COPD.

North america region will lead the global asthma and COPD drugs market over the forecast period 2023 to 2032.

 

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Asthma and COPD Drugs Market 

5.1. COVID-19 Landscape: Asthma and COPD Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Asthma and COPD Drugs Market, By Diseases

8.1. Asthma and COPD Drugs Market, by Diseases Type, 2023-2032

8.1.1. Asthma

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. COPD

8.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Asthma and COPD Drugs Market, By Medication Class

9.1. Asthma and COPD Drugs Market, by Medication Class, 2023-2032

9.1.1. Combination Drugs

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Bronchodilators

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Inhaled Corticosteroids (ICS)

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Short Acting Beta Agonists (SABA)

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Long Acting Beta Agonists (LABA)

9.1.5.1. Market Revenue and Forecast (2020-2032)

9.1.6. Leukotriene Antagonists (LTA)

9.1.6.1. Market Revenue and Forecast (2020-2032)

9.1.7. Anticholinergics

9.1.7.1. Market Revenue and Forecast (2020-2032)

9.1.8. Others

9.1.8.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Asthma and COPD Drugs Market, By Distribution Channel 

10.1. Asthma and COPD Drugs Market, by Distribution Channel, 2023-2032

10.1.1. Hospital Pharmacies

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Retail Pharmacies

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Online Pharmacies

10.1.3.1. Market Revenue and Forecast (2020-2032)

10.1.4. Drug Stores

10.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Asthma and COPD Drugs Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Diseases (2020-2032)

11.1.2. Market Revenue and Forecast, by Medication Class (2020-2032)

11.1.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Diseases (2020-2032)

11.1.4.2. Market Revenue and Forecast, by Medication Class (2020-2032)

11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Diseases (2020-2032)

11.1.5.2. Market Revenue and Forecast, by Medication Class (2020-2032)

11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Diseases (2020-2032)

11.2.2. Market Revenue and Forecast, by Medication Class (2020-2032)

11.2.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Diseases (2020-2032)

11.2.4.2. Market Revenue and Forecast, by Medication Class (2020-2032)

11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Diseases (2020-2032)

11.2.5.2. Market Revenue and Forecast, by Medication Class (2020-2032)

11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Diseases (2020-2032)

11.2.6.2. Market Revenue and Forecast, by Medication Class (2020-2032)

11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Diseases (2020-2032)

11.2.7.2. Market Revenue and Forecast, by Medication Class (2020-2032)

11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Diseases (2020-2032)

11.3.2. Market Revenue and Forecast, by Medication Class (2020-2032)

11.3.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Diseases (2020-2032)

11.3.4.2. Market Revenue and Forecast, by Medication Class (2020-2032)

11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Diseases (2020-2032)

11.3.5.2. Market Revenue and Forecast, by Medication Class (2020-2032)

11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Diseases (2020-2032)

11.3.6.2. Market Revenue and Forecast, by Medication Class (2020-2032)

11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Diseases (2020-2032)

11.3.7.2. Market Revenue and Forecast, by Medication Class (2020-2032)

11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Diseases (2020-2032)

11.4.2. Market Revenue and Forecast, by Medication Class (2020-2032)

11.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Diseases (2020-2032)

11.4.4.2. Market Revenue and Forecast, by Medication Class (2020-2032)

11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Diseases (2020-2032)

11.4.5.2. Market Revenue and Forecast, by Medication Class (2020-2032)

11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Diseases (2020-2032)

11.4.6.2. Market Revenue and Forecast, by Medication Class (2020-2032)

11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Diseases (2020-2032)

11.4.7.2. Market Revenue and Forecast, by Medication Class (2020-2032)

11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Diseases (2020-2032)

11.5.2. Market Revenue and Forecast, by Medication Class (2020-2032)

11.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Diseases (2020-2032)

11.5.4.2. Market Revenue and Forecast, by Medication Class (2020-2032)

11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Diseases (2020-2032)

11.5.5.2. Market Revenue and Forecast, by Medication Class (2020-2032)

11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

Chapter 12. Company Profiles

12.1. Pfizer Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Teva Pharmaceutical Industries Ltd

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Merck & Co. Inc

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Grifols S.A.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Novartis AG

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Cipla Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Abbott

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Astellas Pharma

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Hoffmann-La Roche Ltd

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Glenmark Pharmaceuticals

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

 

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client